Vivos Therapeutics, Inc.VVOS

Vivos Therapeutics (VVOS) reported a net loss of $7.7M in Q1 2026, with cash reserves shrinking to $2.1M, according to its latest 10-Q filing. The company, which markets FDA-cleared oral appliances for obstructive sleep apnea, continues to burn cash despite claiming to offer a 'non-surgical solution' to patients. Its diluted EPS stood at -$0.52, reflecting the pressure on profitability as operating losses widened to $6.6M.

What does VVOS actually do? The company designs and sells devices like the Vivos CARE system, which it claims can 'rehabilitate and restore proper form and function to the airway.' Its products are FDA-cleared for treating severe sleep apnea in adults and children, with over 25,000 children treated to date. However, this apparent clinical traction hasn’t translated to financial stability. Revenue from contracts with customers was $5.1M in Q1 2026-a figure that barely covers a fraction of its R&D and operational costs.

Recent SEC filings highlight governance turmoil. Three 8-K filings in June and July 2026 detailed changes in directors and officers, including the departure of a CFO and the appointment of a new board member. Meanwhile, insider transactions disclosed in Schedule 13D show continued share purchases by a director, even as the company’s stockholders’ equity turned negative (-$1.1M). The firm’s cash burn rate ($6M used in operating activities) and minimal capex ($18K) suggest a tightrope walk between survival and dilution.

The company’s product website touts partnerships and 'landmark technology,' but the financials tell a different story. With liabilities exceeding assets ($26.3M vs. $25.0M), VVOS’s balance sheet resembles a sleep study with more red flags than a restless night’s data. The gap between its polished narrative and stark numbers is wide enough to drive a CPAP machine through.